Menu Search
Equities

Harrow Inc

HROW:NMQ

Harrow Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)46.47
  • Today's Change1.14 / 2.51%
  • Shares traded1.00
  • 1 Year change+217.85%
  • Beta0.7454
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Harrow Inc had net income fall 73.30% from a loss of 14.09m to a larger loss of 24.41m despite a 46.95% increase in revenues from 88.60m to 130.19m.
Gross margin71.16%
Net profit margin-21.78%
Operating margin-5.53%
Return on assets-12.66%
Return on equity-82.97%
Return on investment-14.77%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Harrow Inc fell by 22.19m. Cash Flow from Financing totalled 126.53m or 97.18% of revenues. In addition the company generated 3.84m in cash from operations while cash used for investing totalled 152.55m.
Cash flow per share-0.6172
Price/Cash flow per share--
Book value per share1.65
Tangible book value per share-2.78
More ▼

Balance sheet in USDView more

Harrow Inc has a Debt to Total Capital ratio of 76.08%, a lower figure than the previous year's 757.41%.
Current ratio2.60
Quick ratio2.43
Total debt/total equity3.16
Total debt/total capital0.7608
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items dropped -45.91%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-70.77
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.